Home Cart Sign in  
Chemical Structure| 66575-29-9 Chemical Structure| 66575-29-9

Structure of Forskolin
CAS No.: 66575-29-9

Chemical Structure| 66575-29-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types with binding (IC50=41 nM) to and activation (EC50=0.5 μM) of type I adenylyl cyclase. It is commonly used to raise levels of cAMP in the research of cell physiology.

Synonyms: Coleonol; Colforsin; NSC 375489

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Forskolin

CAS No. :66575-29-9
Formula : C22H34O7
M.W : 410.50
SMILES Code : CC(=O)O[C@H]1[C@H]([C@@H]2[C@]([C@H](CCC2(C)C)O)([C@@]3([C@@]1(O[C@@](CC3=O)(C)C=C)C)O)C)O
Synonyms :
Coleonol; Colforsin; NSC 375489
MDL No. :MFCD00082317
InChI Key :OHCQJHSOBUTRHG-KGGHGJDLSA-N
Pubchem ID :47936

Safety of Forskolin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H312
Precautionary Statements:P280

Related Pathways of Forskolin

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
WT cells 10 µM 48 h To investigate the effect of Forskolin on cell respiration and ATP synthesis, results showed that Forskolin increased cell respiration and ATP synthesis. PMC2814779
CHO-K1 cells 20 µM 30 min Activate PKA to study its effect on KCTD12-induced K+ current desensitization. Results showed that PKA activation significantly slowed KCTD12-induced fast desensitization. PMC4402209
Hippocampal neurons 20 µM 30 min Activate PKA to study its effect on KCTD12-induced K+ current desensitization. Results showed that PKA activation significantly slowed KCTD12-induced fast desensitization. PMC4402209
GLUTag cells 10 μM 15 min and 30 min Measure cAMP concentration and PKA activity PMC8632334
MIN6 cells 10 μM 30 min To assess cAMP production, results showed that forskolin-stimulated cAMP production was significantly reduced in Npas4-overexpressing MIN6 cells PMC3717850
ScN2a-cl3 cells 1 μM 7 days To evaluate the effect of Forskolin on PrPSc levels in differentiated cells. Results showed that Forskolin did not lead to a rebound in PrPSc levels. PMC2777304
HEK293A cells 1–10 μM 1 h To assess the inhibitory effect of Forskolin on mTORC1 activity PMC6529218
MEF cells 10 μM 1 h To assess the inhibitory effect of Forskolin on mTORC1 activity PMC6529218
HEK293T cells 30 μM 30 min Enhanced the interaction between DAGLα and ankyrin-G PMC8384113
Primary cortical neurons 30 μM 30 min Increased the interaction between DAGLα and ankyrin-G and regulated dendritic spine morphology PMC8384113

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice PSNL and CFA models Oral 2 mg/kg Once daily for 14–33 days Forskolin reversed the PSNL- or CFA-induced decrease in PKA and CREB phosphorylation and BDNF expression, and partially reversed mechanical hypersensitivity and depression-like behaviors PMC11487153
Mice Not specified Intraperitoneal injection 1 mg/kg Single dose, lasting 30 minutes Enhance endothelial cell barrier function, reduce permeability and immune complex deposition PMC2213287
Mice WT and AnkG cKO mice Intraperitoneal injection 0.2 mg/kg Single injection, behavioral tests conducted 30 minutes after injection Evaluated the effect of forskolin on depression- and anxiety-related behaviors, finding that forskolin could not reverse depression-related behavior in AnkG cKO mice but could reverse anxiety-related behavior PMC8384113

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03390985 - Completed - -
NCT02586883 Idiopathic Dilation of the Bro... More >>nchi Less << Not Applicable Recruiting April 2020 France ... More >> Necker-Enfants Malades Hospital Recruiting Paris, France, 75015 Contact: Isabelle SERMET-GAUDELUS, MD, PhD    +33144494887    isabelle.sermet@nck.aphp.fr Less <<
NCT03455153 - Completed - United Kingdom ... More >> Lindum Medical Practice Lincoln, Lincolnshire, United Kingdom, LN2 2JP Nettleham Medical Practice Lincoln, Lincolnshire, United Kingdom, LN2 2RS Birchwood Medical Practice Lincoln, Lincolnshire, United Kingdom, LN6 0QQ Less <<
NCT01920841 Weight Loss Not Applicable Withdrawn(Study Design changed... More >> and will be resubmitted as a new study) Less << - United States, Louisiana ... More >> Pennington Biomedical Research Center Baton Rouge, Louisiana, United States, 70808 Less <<
NCT03652090 - Completed - -
NCT02143349 Metabolic Syndrome ... More >> Obesity Less << Phase 3 Unknown May 2015 Australia, Victoria ... More >> College of Health and Biomedicine Victoria University Recruiting St. Albans, Victoria, Australia, 14428 Contact: Dr. Xiao Su    +61399192318    xiao.su@vu.edu.au    Contact: A/Prof Michael Mathai    +61399192211    michael.mathai@vu.edu.au    Principal Investigator: Dr. Xiao Su          Sub-Investigator: A/Prof Michael Mathai Less <<
NCT00864578 - Withdrawn(loss of interest bef... More >>ore enrolment started) Less << June 2009 Italy ... More >> Ophthalmology Department of the University Clinic Bari, Italy, I-70124 Less <<
NCT02807415 - Recruiting June 2019 Germany ... More >> Justus-Liebig-University Recruiting Gießen, Germany, 35385 Contact: Lutz Nährlich, MD    004964198557620    lutz.naehrlich@paediat.med.uni-giessen.de    Contact: Claudia Rückes-Nilges, Dipl-Biol    004964198556945    claudia.rueckes-nilges@paediat.med.uni-giessen.de    Principal Investigator: Lutz Nährlich, MD          Sub-Investigator: Stefan Kuhnert, MD          Hannover Medical School Recruiting Hannover, Germany, 30625 Contact: Burkhard Tümmler, MD PhD    00495115322920    tuemmler.burkhard@mh-hannover.de    Contact: Christian Dopfer, MD    00495115326111    dopfer.christian@mh-hannover.de    Principal Investigator: Burkhard Tümmler, MD PhD          Sub-Investigator: Christian Dopfer, MD          University of Heidelberg Recruiting Heidelberg, Germany, 69120 Contact: Marcus Mall, MD    00496221564502    Marcus.Mall@med.uni-heidelberg.de    Contact: Simon Gräber, MD    004962215638926    Simon.Graeber@med.uni-heidelberg.de    Principal Investigator: Marcus Mall, MD          Sub-Investigator: Simon Gräber, MD          Sub-Investigator: Susanne Dittrich, MD Less <<
NCT00863811 - Withdrawn(loss of interest bef... More >>ore enrolment started) Less << July 2009 Italy ... More >> Ophthalmology Department of the University Bari, Italy, I-70124 Less <<
NCT01254006 Glaucoma Not Applicable Completed - Italy ... More >> Univerisity La Sapienza Latina, Italy Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.44mL

0.49mL

0.24mL

12.18mL

2.44mL

1.22mL

24.36mL

4.87mL

2.44mL

References

 

Historical Records

Categories